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BACKGROUND: Focal adhesion kinase (FAK) is overexpressed in a variety of cancers, such as breast, colon, prostate, ovary, and lung
cancers. However, the mechanism by which extracellular matrix fibronectin stimulates lung cancer cell migration and invasion through
FAK remains to be investigated.
METHODS: The signalling pathways in fibronectin-mediated lung cancer cell migration and invasion were examined using western
blotting. The metastasis function was detected by wound healing, migration and invasion assays. Further, RNA interference and kinase
inhibitors were also used to study the downstream signals.
RESULTS: In this study, we examined the FAK signalling pathways in relation to calpain-2 and RhoA in fibronectin-mediated lung cancer
cell migration and invasion. We found that A549 lung epithelial cells stimulated by fibronectin showed increased phosphorylation of
FAK and its downstream targets, Src, ERK1/2, phosphatidylinositol 30-kinase (PI3K), and Akt. Consistent with this observation,
depletion of FAK by siRNA resulted in the inhibition of Src, ERK1/2, PI3K, and Akt activity. In addition, the Src inhibitor, PP2, blocked
the phosphorylation of FAK, ERK1/2, PI3K, and Akt. Conversely, inhibition of MEK1/2 using PD98059 reduced the expression of
matrix metalloproteinase-9 (MMP9) and calpain-2. The PI3K inhibitor, LY294002, further blocked the expression of MMP9 and
RhoA. Inhibition of both MEK1/2 and PI3K caused reduced cell migration and invasion.
CONCLUSIONS: Our data suggest that fibronectin-mediated activation of FAK that leads to lung cancer metastasis could occur through
ERK or PI3K/Akt regulation of MMP9/calpain-2 or MMP9/RhoA activity, respectively.
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Lung cancer is one of the most common types of cancer in the
world. The major health threat for lung cancer is death due to
metastasis, a multi-step process requiring the ability of cancer cells
to escape control of their surrounding microenvironment and
invade the basement membrane. Focal adhesion kinase (FAK), a
cytoplasmic kinase that is involved in extracellular matrix (ECM)/
integrin-mediated signalling pathways, has been suggested to have
an essential role in metastasis, through the modulation of tumour
cell migration and invasion (Schaller et al, 1992). After integrin
activation, FAK exhibits increased kinase activity through
phophorylation at its Tyr397 site (Lipfert et al, 1992). Indeed,
FAK activity was found to be upregulated in cancer cell lines and
in tissue lysates obtained from patients with metastatic disease
(Cance et al, 2000). An important role of FAK in cancer cell
invasion was further supported by RNA interference (RNAi)
studies (Huang et al, 2005) and by the use of a specific FAK
inhibitor to block metastasis (van Nimwegen et al, 2005).
Activated FAK in cancer cells relays signals through multiple
downstream targets. For example, when FAK is activated through
autophosphorylation at Tyr397, it binds the Src-homology domain
2 (SH2) of phosphatidylinositol 30-kinase (PI3K), thereby trans-
porting the catalytic subunit of PI3K to the membrane, where it
catalyzes the phosphorylation of inositol lipids at the D-3 position
to form 30-phosphorylated phosphoinositides, including phospha-
tidylinositol- 3,4,5-trisphosphate (Chen et al, 1996). The residues
surrounding Tyr397 can also constitute a sequence that binds to
the SH2 motif of other tyrosine kinases, such as pp60
c src. Binding
of FAK to pp60
c src also links FAK to the adaptor protein Grb2 and
to the Ras signalling pathway (Schlaepfer and Hunter, 1997;
Schlaepfer et al, 1998). The downstream targets of the Ras
signalling pathway include ERK1/2 (Sanders and Basson, 2000).
Indeed, these pathways are activated during integrin binding to the
ECM, resulting in the transduction of external stimuli from the
ECM to the nucleus (Sawai et al, 2005).
In cancer cells, FAK has been shown to regulate cell migration
and invasion through distinct pathways by promoting the dynamic
regulation of focal adhesion and peripheral actin structures
(Lauffenburger and Horwitz, 1996; Friedl and Bro ¨cker, 2000;
Schlaepfer et al, 2004), as well as the matrix metalloproteinases
(MMP)-mediated matrix degradation (Siesser and Hanks, 2006). In
order to migrate, the leading edge of the cell forms peripheral
adhesions, whereas the rear part of the cell breaks down into focal
adhesions. On the other hand, calpain critically regulates cell
motility through its involvement in the disassembly of focal
adhesion. Consistent with these views, tumours that have
metastasised have been found to have higher levels of calpain
than those that are not metastatic (Carragher et al, 2003). In
separate studies, RhoA has been implicated in the regulation of the
contraction and retraction forces that are required for cell migration
(Etienne-Manneville and Hall, 2002; Raftopoulou and Hall, 2004).
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but re-expression of FAK in these cells decreased RhoA activity (Ren
et al, 2000). Together, these findings concur with the observation
that the metastatic capability correlates with MMP9 expression in
tumour cells (Bjo ¨rklund and Koivunen, 2005). Indeed, the enhanced
expression of MMP-9 has been associated with human lung cancer
invasion and metastasis (Yang et al,2 0 0 5 ) .
Although there are numerous suggestions that the ECM
promotes cancer cell migration and invasion through FAK
signalling, the mechanism by which ECM fibronectin regulates
FAK activity in lung cancer cells, particularly in relation to calpain-2
and RhoA, has not yet been explored in detail. In this study, we
propose that fibronectin-induced stimulation of FAK that causes
lung cancer cell migration and invasion occurs by the activation of
MMP9/calpain-2 and MMP9/RhoA through the ERK and PI3K/Akt
signalling pathways, respectively.
MATERIALS AND METHODS
Antibodies and reagents
FAK (clone 4. 47) and p-FAK (Tyr397) antibodies were from Upstate
Biologicals Inc. (New York, NY, USA). p-FAK (Tyr861) was obtained
from BioSource International (Camarillo, CA, USA). p-FAK
(Tyr925), p-Src (Tyr416), Src, p-PI3K p85 (Tyr458)/p55 (Tyr199),
PI3K p85, p-Akt (Ser473), p-ERK1/2 (Thr202/Tyr204), and RhoA
(67B9) antibodies were from Cell Signaling Technology Inc
(Danvers, MA, USA). ERK2 (C-14), Akt1(C-20), MMP-9 (C-20),
calpain-2 (N-19), and GAPDH (1D4) antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PP2,
PD98059, and LY294002 were from Calbiochem (San Diego, CA,
USA). The FAK SMARTpool siRNA, control siRNA, and the
transfection reagent were obtained from Dharmacon (Lafayette,
CO, USA). Fibronectin from human plasma was from Sigma-Aldrich
(New York City, NY, USA).
Cell culture
The A549 human lung cancer cell line was obtained from the
American Type Culture Collection (Manassas, VA, USA) and
cultured in Ham’s F12K medium (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA) at
371C with 5% CO2.
Wound healing assay
Cells were plated into 24-well plates and grown to confluence. The
monolayer was wounded using the tip of a sterile 200-ml pipette
(width: B1mm). Cell debris were removed by washing twice with
the serum-free medium. The cells were then allowed to migrate
into the denuded areas for 10h. Photomicrographs were taken
immediately after wounding and following 10h of incubation using
the Nikon Diaphot TMD inverted microscope (Nikon, Chiba,
Japan). The percentage (%) change in migration was determined
by comparing the difference in wound width (n¼3).
Migration assay
Transwell plates (24-well, 8-mm pore size; Costar, Cambridge, MA,
USA) were used to conduct the migration assay. The lower
chamber of the transwell plates were filled with 500ml of Ham’s
F12K medium containing 10% FBS. Cells (5 10
4) suspended in
Ham’s F12K medium that contained 1% FBS were added to the
upper chamber, and the plate was incubated at 371C with 5% CO2
for 6h. Cells on the upper surface of the filters were removed using
cotton swabs. Cells that migrated to the lower surface of the filters
were washed, fixed, and stained with hematoxylin and eosin, and
counted under the microscope. The percentage change in
migration was determined by counting the number of cells that
migrated to the lower surface of the filters. At least three separate
microscopic fields were counted per membrane (n¼3).
Invasion assay
Cell invasion through a three-dimensional ECM was assessed using
BD Matrigel invasion chambers (BD, Biocoat, Bedford, MA, USA)
with 8.0-mm filter membranes. Cells (5 10
4) re-suspended in
500ml of Ham’s F12K medium that contained 1% FBS were plated
into the chamber inserts, and those re-suspended in 750mlo f
Ham’s F12K that contained 10% FBS were placed into the lower
chamber. After 24h, cells invading the lower surface of the filters
were fixed, stained, and counted. The percentage change in
invasion was determined by counting the number of cells that
migrated to the lower surface of the filters. At least three separate
microscopic fields were counted per membrane (n¼3).
RNA interference
A549 lung cancer cells were transfected with FAK siRNA or control
non-specific siRNA according to the manufacturer’s instructions.
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Figure 1 Fibronectin induces the migration and invasion of A549 lung cancer cells. (A) A549 cells (5 10
4) suspended in media with or without
fibronectin (10mgml
 1) were seeded in the upper chamber of transwell plates (Costar, Cambridge, MA, USA). After 6h of incubation at 371C, cells that
migrate to the lower surface of the filters were fixed, stained, and quantified by counting three randomly selected fields under the microscope. (B) A549 cells
were plated in 35-mm culture dishes and grown to 100% confluence. After generating a single scratch in the monolayer, the cells were washed with PBS, and
cultured for another 10h in media with or without fibronectin. Photographs were taken immediately after wounding and 10h later. The change in wound
width was measured as described in the Materials and methods section. (C) A549 cells (5 10
4) suspended in media with or without fibronectin were
seeded in Matrigel invasion inserts (BD, Franklin Lakes, NJ, USA). After 24h in culture, cells that invaded the lower surface of the filters were counted. Values
are means±s.d. (n¼3). Migration and invasion of control cells were set at 100%. Significant difference (*) in migration and invasion was set at Po0.05.
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siRNA at a concentration of 200pmol per well. Depletion of FAK
was determined by western blotting. The functional effects of FAK
on fibronectin-induced A549 cell migration and invasion were
evaluated by wound healing, migration, and invasion assays as
described above.
Western blot analysis
Cells were harvested and solubilised in the lysis buffer (50mM Tris-
HCl, pH 7.5, 150mM NaCl, 1mM CaCl2, 1% Triton X-100, 0.1%
SDS, 0.1% Nonidet P-40, 2mM PMSF, 1mM vanadate, 5mgml
 1
Trasylol, 10mM Pepstatin A, and 10mM leupeptin). Protein quantity
was determined using the Bradford protein assay (Bio-Rad,
Hercules, CA, USA), and 50mg of total protein from each sample
was resolved by SDS–PAGE gels and blotted onto polyvinylidene
difluoride membranes (Nihon Millipore Ltd, Tokyo, Japan).
Membranes were probed overnight with the appropriate primary
antibodies at 41C followed by incubation with HRP-conjugated
secondary antibodies at room temperature for 1h. Immunoreac-
tive bands were detected using the ECL system (Amersham,
Piscataway, NJ, USA). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) blots served as controls.
Statistical analysis
Experiments were performed at least three times. Results are
expressed as means±s.d. One-way ANOVA was used to determine
the overall significance within data groups. A P-value of o0.05 was
considered significant.
RESULTS
Fibronectin stimulates the migration and invasion of A549
human lung adenocarcinoma cells through the activation
of FAK
Interactions between tumour cells and the ECM strongly influence
tumour development. Fibronectin, a large multi-domain ECM
glycoprotein, regulates many cellular processes, including migra-
tion and invasion (Shibata et al, 1998; Sawai et al, 2005). In human
lung adenocarcinoma cells, the involvement of fibronectin in these
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Figure 2 Fibronectin promotes A549 cell migration and invasion through FAK. (A) A549 cells were seed in media with or without fibronectin
(10mgml
 1) and incubated at 371C at the indicated time points. The expression of FAK phosphorylated at Tyr397, Tyr861, and Tyr 925 was then evaluated
by western blotting. (B) A549 cells transfected with FAK siRNA or control siRNA for 48h were re-plated in 35-mm dishes. Migration was evaluated as
described in Figure 1. Depletion of FAK was determined by western blotting. (C) A549 cells transfected with FAK siRNA or control siRNA for 48h were
suspended in media with or without fibronectin and seeded in the upper chamber of transwell plates. The migration of cells to the lower surface of the filters
was assessed after 6h as described in Figure 1. Invasion assay of A549 cells transfected with FAK siRNA or control siRNA for 48h was also carried out as
described in Figure 1. Values are means±s.d. (n¼3). Migration and invasion of control cells were set at 100%. Significant difference (*) in migration and
invasion was set at Po0.05.
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sprocesses remains to be investigated. Therefore, we sought to
characterise the role of fibronectin in the migration and invasion
of A549 human lung adenocarcinoma cells. Using in vitro transwell
migration assays, we found that fibronectin, indeed, induces the
migration of A549 lung adenocarcinoma cells (Figure 1A).
Furthermore, in vitro wound healing assays showed that fibro-
nectin is capable of inducing migration (0.325 vs 0.625mm: 100 vs
192% migration) of A549 cells into the wounded area (Figure 1B).
As the acquisition of an invasive phenotype by cancer cells is a
critical step for tumour progression, we also examined the invasive
ability of fibronectin-treated A549 cells through a three-dimen-
sional matrigel-coated filter. As shown in Figure 1C, fibronectin-
treated A549 cells had increased ability to traverse matrigel-coated
filters compared with untreated control cells. Taken together, these
data indicate that fibronectin can stimulate the migration and
invasion of lung cancer cells.
Next, we investigated the molecular mechanism through which
fibronectin induces the migration and invasion of lung cancer
cells. As previous studies have shown that the ECM ligand–
integrin interaction leads to tyrosine phosphorylation of FAK,
which is crucial for tumour progression, we sought to examine
whether fibronectin could promote tyrosine phosphorylation of
FAK in A549 lung adenocarcinoma cells. Indeed, we found that
fibronectin significantly enhanced the phosphorylation of FAK at
tyrosine 397, tyrosine 861, and tyrosine 925 residues (Figure 2A),
suggesting that fibronectin-induced migration and invasion of
A549 cells may be a result of FAK activation. To substantiate this
finding, we depleted FAK by siRNA treatment and examined the
effect of FAK depletion on fibronectin-mediated migration and
invasion of A549 cells. As shown in Figure 2B and C, there was a
dramatic inhibition of fibronectin-induced migration (0.56 vs
0.1mm: 100 vs 18%) and invasion in FAK-depleted A549 cells,
suggesting a critical role of FAK activation in these processes.
FAK-induced A549 migration and invasion occur through
Src, ERK, and PI3K/Akt activation
To investigate the potential mechanism of FAK signalling in lung
cancer cell migration and invasion, we examined the activation of
the downstream signalling molecules of integrin. We found that
A549 cells treated with fibronectin showed increased phosphoryla-
tion of Src, ERK, PI3K, Akt, (Figure 3A), and JNK (data not shown)
in a time-dependent manner. Thus, it appears that fibronectin-
associated FAK signalling in lung cancer cells occurs through Src,
ERK, PI3K, Akt, and JNK. We then examined changes in the
activation of these molecules after the depletion of FAK by siRNA
in A549 cells. As shown in Figure 3B, the levels of p-Src, p-ERK1/2,
p-PI3K, and p-Akt in these cells were reduced. No change in p-JNK
was observed (data not shown). Taken together, our results suggest
that fibronectin-mediated stimulation of lung cancer cell migration
and invasion by FAK is achieved through Src, ERK1/2, and PI3K/
Akt signalling pathways.
FAK promotes A549 migration and invasion of lung cancer
cells through cross talk with Src, and Src regulation of ERK
and PI3K/Akt
In many signalling milieus, the FAK–Src interaction serves to
control cell motility, but the mechanism underlying its activity is
only partly understood. As indicated above, we found that the
depletion of FAK caused decreased phosphorylation of Src. To
further characterise the relationship between FAK and Src, we also
examined the consequence of Src inhibition on the phosphoryla-
tion of FAK in A549 cells grown in fibronectin-coated plates. Our
results showed that upon treatment of A549 cells with the Src
inhibitor, PP2, phosphorylation of FAK at its Tyr397, Tyr861, and
Tyr925 residues was noticeably reduced (Figure 4A), indicating
that Src also has an important role in the regulation of FAK and its
downstream targets. Indeed, FAK-associated phosphorylation of
ERK1/2, PI3K, and Akt was also reduced in PP2-treated cells
(Figure 4A). In addition, compared with control cells, the
migration and invasive ability of A549 cells decreased in the
presence of PP2 (Figure 4B). Taken together, these data further
suggest that the FAK–Src interaction promotes the invasion and
migration of A549 lung cancer cells through the ERK1/2 and PI3K/
Akt pathways.
FAK promotes A549 cell invasion and migration through
regulation of MMP9 and calpain-2 expression via ERK1/2
To further examine the involvement of ERK1/2 in FAK signalling
during A549 cell migration and invasion, we took advantage of the
availability of PD98059, an inhibitor of the ERK1/2 upstream
kinase, MEK1/2. As shown in Figure 5A, PD98059 treatment of
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Figure 3 FAK promotes A549 lung cancer cells migration and invasion through Src, ERK, and PI3K/Akt. (A) A549 cells were seeded in media with or
without fibronectin (10mgml
 1) and incubated at 371C at the indicated time points. (B) A549 lung cancer cells transfected with FAK siRNA or control
siRNA for 48h were seeded in media with fibronectin and incubated at 371C for 2h. Cell lysates were analysed by western blotting using the indicated
antibodies. (C) Quantitation of p-Src levels (in square pixels) in FAK siRNA- and control siRNA-treated cells was assessed by densitometric analysis using the
NIH Image J software (NIH Image, Bethesda, MD, USA).
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sA549 cells resulted in a significant inhibition of the migration and
invasion of these cells, supporting our view that FAK promotes
A549 cell invasion and migration through ERK1/2.
As FAK has been suggested to regulate cell migration and
invasion by promoting MMP-mediated matrix degradation
(Shibata et al, 1998) and focal adhesion dynamics (Glading et al,
2000; Shao et al, 2006), which is regulated by calpain (Glading et al,
2000; Huang et al, 2004), we next sought to determine whether
MMP9 and calpain-2 expression is regulated through ERK1/2.
Using western blotting, we found that A549 cells treated with
PD98059 showed decreased expression of both MMP9 and calpain-
2 (Figure 5B), suggesting that ERK1/2 regulates the expression of
these proteins in A549 lung cancer cells. Taken together, our
data suggest that FAK promotes A549 cell invasion and
migration through ERK1/2-MMP9 and ERK1/2-calpain-2 signal-
ling mechanisms.
FAK promotes A549 cell invasion and migration through
the regulation of MMP9 and RhoA expression via PI3K
To examine the potential involvement of PI3K in FAK signalling,
we examined the effect of the PI3K inhibitor, LY294002, on the
migration and invasion of A549 cells. As shown in Figure 6,
treatment with LY294002 caused a significant decrease in the
migration and invasion of A549 cells, suggesting that FAK-
mediated A549 cell invasion and migration involves PI3K
signalling. As both MMP-mediated matrix degradation and
RhoA-mediated regulation of contraction and retraction forces
have been implicated in FAK-induced cell migration and invasion
(Lim et al, 2008; Luo et al, 2009), we further examined the
expression of MMP9 and RhoA in A549 cells treated with
LY294002. As shown in Figure 6B, both MMP9 and RhoA
expression was reduced in cells treated with LY294002, indicating
that the expressions of these proteins were regulated through PI3K
signalling. Therefore, in addition to ERK1/2-MMP9 and ERK1/2-
calpain-2 signalling, FAK also promotes A549 cell invasion and
migration through the PI3K/Akt-MMP9 and PI3K/Akt-RhoA
pathways.
To summarise our results, fibronectin-stimulated A549
cell migration and invasion is achieved through the activation
of FAK, which regulates calpain/MMP-9 and RhoA/MMP9 expres-
sion through ERK1/2 and PI3K/Akt signalling, respectively
(Figure 7).
DISCUSSION
The ECM regulates many cellular events, such as cell differentia-
tion, proliferation, and apoptosis. In many cells, it has been shown
that activation of the mitogen-activated protein kinase (MAPK)
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Figure 5 ERK promotes A549 lung cancer cell migration and invasion
through MMP9 and calpain-2. (A) Migration and invasion assays of A549
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(Sawai et al, 2005). Furthermore, integrin receptor binding to ECM
proteins seems to activate FAK, which is also involved in the
regulation of cellular events, such as cell migration and invasion
(Sanders and Basson, 2000; Sawai et al, 2005).
Our current findings indicate that the ECM glycoprotein,
fibronectin, specifically promotes A549 lung cancer cell migration
and invasion. Consistent with previous reports that FAK has a
critical role in promoting cell migration and invasion (Mukho-
padhyay et al, 2005; Zeng et al, 2006), we found an increased
activation of FAK in A549 cells grown in fibronectin-coated plates.
Focal adhesion kinase activation was determined by increased
phosphorylation of FAK at its Tyr397, Tyr861, and Tyr925
residues. The relevance of FAK in fibronectin-mediated cell
invasion and migration was supported by our data showing that
these processes are inhibited after the depletion of FAK by siRNA.
The signalling events downstream of FAK that affect cellular
migration and invasion are complex. For example, autopho-
sphorylation of FAK at Tyr397 due to integrin engagement creates
high affinity binding for Src, which then gets activated. In turn,
activated Src phosphorylates FAK at Tyr397, Tyr861, and Tyr925
residues (Calalb et al, 1995, 1996). Focal adhesion kinase activation
through Tyr925 phosphorylation and recruitment of GRB2 into the
FAK–Src complex lead to enhanced activation of targets, such as
ERK1/2 (Schlaepfer and Hunter, 1996). In addition, FAK
phosphorylation at Tyr397 mediates its interaction with the SH2
domain of the p85 subunit of PI3K (Chen et al, 1996).
To better understand the mechanism by which FAK regulates
fibronectin-induced cell migration and invasion, we examined the
expression and activity of the downstream targets of integrin
receptors. Consistent with previous findings in other cell types
(Sanders and Basson, 2000; Schmitz et al, 2005; Vulin et al, 2005;
Stulic et al, 2007), we found an enhanced activation of Src, ERK,
PI3K, and Akt in A549 lung cancer cells. The role of FAK in the
activation of these effectors was noted through their down-
regulated activation after the depletion of FAK. On the basis of our
results, it appears that FAK promotes fibronectin-mediated lung
cancer metastasis through the activation of Src, ERK, PI3K, and
Akt. Although JNK has been implicated in FAK signalling that
promotes cell invasion and migration (Hauck et al, 2001; Hsia
et al, 2003), its apparent lack of involvement in fibronectin-
mediated FAK signalling in lung cancer cells may indicate distinct
responses by different cell types to different ligands. Alternatively,
JNK may be activated through other direct or indirect integrin
signalling pathways.
In this study, we further examined whether Src affects FAK
activation, and also studied the manner by which the interaction
between FAK and Src regulates their downstream targets. Upon
treatment of A549 cells with the PP2 Src inhibitor, we found
reduced activation of FAK as evidenced by reduced phosphoryla-
tion at its Tyr397, Tyr861, and Tyr925 residues. We also showed
the inhibition of ERK1/2 and PI3K/AKT in PP2-treated cells. Thus,
it seems that FAK promotes A549 lung cancer cell migration and
invasion in concert with Src and subsequent activation of the ERK
and PI3K/Akt signalling pathways.
The involvement of FAK-stimulated ERK1/2 signalling in
fibronectin-induced A549 lung cancer cell migration and invasion
was supported by our observation that these processes are
inhibited in cells treated with PD98059, an inhibitor of the
ERK1/2 upstream kinase, MEK. Studies in ovarian carcinoma cells
have shown that FAK and ERK1/2 are important for fibronectin-
stimulated invasiveness and MMP9 secretion by these cells
(Shibata et al, 1998). Moreover, it was found that the MMP9 gene
promoter is partially regulated through activation of the ERK1/2
pathway (Gum et al, 1997). Thus, in an effort to understand the
specific role of ERK1/2 in A549 cell migration and invasion, we
examined the expression of MMP9 in A549 cells treated with
PD98059. Our finding that these cells have decreased MMP9
expression points to the involvement of this protein in A549 cell
migration and invasion. This is consistent with the fact that MMP9
is involved in the degradation of matrix components and thus
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Figure 6 PI3K promotes A549 lung cancer cell migration and invasion
through MMP9 and RhoA. (A) Migration and invasion assays of A549 cells
pretreated with LY294002 or DMSO for 48h were carried out as
described in Figure 4, except that LY294002 was used as treatment instead
of PP2. Values are means±s.d. (n¼3). Migration and invasion of control
cells were set at 100%. Significant difference (*) in migration and invasion
was set at Po0.05. (B) A549 cells pretreated with LY294002 or DMSO
and seeded in media containing fibronectinþLY294002 or fibronec-
tinþDMSO were harvested after 48h, and analysed by western blotting
using the indicated antibodies.
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Figure 7 Fibronectin-mediated FAK signalling pathways in lung cancer
cell migration and invasion. Fibronectin-stimulated A549 cell migration and
invasion is achieved through the activation of FAK, which regulates calpain/
MMP-9 and RhoA/MMP9 expression through ERK1/2 and PI3K/Akt
signalling, respectively.
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brane barriers. Therefore, it appears that FAK promotes A549 lung
cancer cell invasion through the ERK/MMP9 pathway.
Previous studies have shown that calpain proteases are required
for rear de-adhesion during productive motility whether initiated
by adhesion-related signals or growth factors (Glading et al, 2000).
For example, EGF-induced cell de-adhesion and migration require
the activation of the calpain-2 isoform by MAPK at the cell
membrane (Shao et al, 2006). Our hypothesis was that calpain-2
promotes cell migration through ERK signalling. Indeed, treatment
of A549 lung cancer cells with PD98059 caused a decrease in the
expression of calpain-2. Taken together, our findings support the
view that fibronectin induces the activation of FAK which then
activates both the ERK1/2/MMP9 and ERK1/2/calpain-2 pathways
to promote lung cancer cell invasion and migration, respectively.
There have been suggestions that activation of PI3K regulates
the migration and invasion of various cancer cells (Reiske et al,
1999; Zeng et al, 2006). Despite these findings, the specific role of
PI3K in controlling lung cancer cell migration and invasion,
particularly in relation to FAK signalling, has been elusive. In this
study, we found that PI3K lies downstream of FAK. Inhibition of
PI3K in A549 lung cancer cells by LY294002, showed decreased
migration and invasive ability of A549 cells, suggesting that PI3K is
also involved in the fibronectin-induced FAK signalling. As with
ERK, PI3K has been implicated in the activation of MMP-9
secretion (Han et al, 2006), and as with calpain, RhoA regulates the
contraction and retraction forces that are required for cell motility
(Raftopoulou and Hall, 2004). In this study, we examined the
potential signalling between PI3K and MMP9 or RhoA in A549
cells exposed to fibronectin and found that MMP9 and RhoA
expression decreased upon LY294002 treatment, suggesting that
FAK further promotes A549 lung cancer cell invasion and
migration through PI3K/MMP9 and PI3K/RhoA signalling
mechanisms.
Although our RhoA finding contradicts the observation of
Chen et al (2002), it is consistent with the finding of Amano et al
(1996) who reported that RhoA could increase the level of
phosphorylated myosin, which crosslinks actin filaments and
generates contractile forces, promoting movement of the cell
body and facilitating cell rear detachment. The difference in our
finding from that of Chen et al (2002) may be due to the effect of
ROCK, which has been shown to positively regulate cell motility
together with RhoA, but was also found to negatively affect cell
motility depending on cellular conditions (Kimura et al, 1996;
Maekawa et al, 1999). Nevertheless, our study provides the first
indication that fibronectin-induced FAK activation stimulates cell
migration and invasion through PI3K/MMP-9 and PI3K/RhoA
signalling.
In summary, we provide compelling evidence that fibronectin-
induced A549 cell migration and invasion occurs through the
activation of FAK, which then regulates MMP-9 expression
through ERK or PI3K, as well as calpain-2 and RhoA expression
through ERK and PI3K, respectively. A model for these
fibronectin-mediated FAK signalling mechanisms is shown in
Figure 7. Certainly, these signalling pathways may have critical
roles in lung cancer metastasis. Our findings also offer new
insights into the potential therapeutic significance of FAK in lung
cancer.
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